[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR128760A1 - Vectores de expresión con promotores dobles bidireccionales y sus usos - Google Patents

Vectores de expresión con promotores dobles bidireccionales y sus usos

Info

Publication number
AR128760A1
AR128760A1 ARP230100603A ARP230100603A AR128760A1 AR 128760 A1 AR128760 A1 AR 128760A1 AR P230100603 A ARP230100603 A AR P230100603A AR P230100603 A ARP230100603 A AR P230100603A AR 128760 A1 AR128760 A1 AR 128760A1
Authority
AR
Argentina
Prior art keywords
seq
sequence
reverse complement
hhcr1
promoter sequence
Prior art date
Application number
ARP230100603A
Other languages
English (en)
Inventor
Carmen Barnes
Yogeshwar Sharma
Omar Francone
Hillard Rubin
Wei Wang
Gustavo Cerqueira
Serena Nicole Dollive
Andrew Pla
Original Assignee
Homology Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Homology Medicines Inc filed Critical Homology Medicines Inc
Publication of AR128760A1 publication Critical patent/AR128760A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14051—Methods of production or purification of viral material
    • C12N2750/14052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente descripción se proporcionan polinucleótidos que comprenden novedosos casetes de expresión dobles bidireccionales, virus adenoasociados recombinantes (rAAV) que comprenden estos polinucleótidos, y métodos para producir y usar los polinucleótidos y rAAV. Se proporcionan, además, novedosos elementos de control de la transcripción (por ejemplo, promotores, potenciadores, intrones, secuencias de poliadenilación y sus combinaciones) y novedosas secuencias codificantes de anticuerpos. Las composiciones y los métodos descritos en la presente descripción son particularmente ventajosos porque permiten la expresión eficiente de dos polipéptidos diferentes (por ejemplo, una cadena pesada de anticuerpo y una cadena ligera de anticuerpo) en una célula. En particular, permiten la expresión eficiente de anticuerpos (por ejemplo, anticuerpos anti-C5) en un sujeto, para el tratamiento de enfermedades (por ejemplo, enfermedades mediadas por C5, tales como HPN). Reivindicación 1: Un polinucleótido aislado que comprende de 5’ a 3’: (a) una secuencia promotora de a1-antitripsina humana (hAAT) de complemento inverso y una secuencia de la región humana 1 de control hepático (hHCR1); (b) una secuencia promotora de hAAT de complemento inverso que es al menos 85% idéntica a la SEQ ID Nº 17 y una secuencia de hHCR1 que es al menos 85% idéntica a la SEQ ID Nº 22; (c) una secuencia promotora de hAAT de complemento inverso que es al menos 85% idéntica a la SEQ ID Nº 17 y una secuencia de hHCR1 de complemento inverso que es al menos 85% idéntica a la SEQ ID Nº 23; (d) una secuencia promotora de hAAT de complemento inverso que es al menos 85% idéntica a la SEQ ID Nº 18 y una secuencia de hHCR1 que es al menos 85% idéntica a la SEQ ID Nº 22; (e) una secuencia promotora de hAAT de complemento inverso que es al menos 85% idéntica a la SEQ ID Nº 18 y una secuencia de hHCR1 de complemento inverso que es al menos 85% idéntica a la SEQ ID Nº 23; (f) una secuencia promotora de hAAT de complemento inverso que es al menos 85% idéntica a la SEQ ID Nº 20 y una secuencia de hHCR1 que es al menos 85% idéntica a la SEQ ID Nº 22; (g) una secuencia promotora de hAAT de complemento inverso que es al menos 85% idéntica a la SEQ ID Nº 20 y una secuencia de hHCR1 de complemento inverso que es al menos 85% idéntica a la SEQ ID Nº 23; (h) una secuencia promotora de hAAT de complemento inverso que es al menos 85% idéntica a la SEQ ID Nº 17 y una secuencia de hHCR1 que es al menos 85% idéntica a la SEQ ID Nº 24; (i) una secuencia promotora de hAAT de complemento inverso que es al menos 85% idéntica a la SEQ ID Nº 18 y una secuencia de hHCR1 que es al menos 85% idéntica a la SEQ ID Nº 24; (j) una secuencia promotora de hAAT de complemento inverso que es al menos 85% idéntica a la SEQ ID Nº18 y una secuencia de hHCR1 de complemento inverso que es al menos 85% idéntica a la SEQ ID Nº 25; (k) una secuencia promotora de hAAT de complemento inverso que es al menos 85% idéntica a la SEQ ID Nº 20 y una secuencia de hHCR1 que es al menos 85% idéntica a la SEQ ID Nº 24; o (l) una secuencia promotora de hAAT de complemento inverso que es al menos 85% idéntica a la SEQ ID Nº 20 y una secuencia de hHCR1 de complemento inverso que es al menos 85% idéntica a la SEQ ID Nº 25. Reivindicación 80: El rAAV de cualquiera de las reivindicaciones 55 - 71, el polinucleótido de cualquiera de las reivindicaciones 1 - 45, el genoma de rAAV de cualquiera de las reivindicaciones 46 - 54 o la composición farmacéutica de acuerdo con la reivindicación 72, para usar como un medicamento.
ARP230100603A 2022-03-11 2023-03-10 Vectores de expresión con promotores dobles bidireccionales y sus usos AR128760A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263269192P 2022-03-11 2022-03-11

Publications (1)

Publication Number Publication Date
AR128760A1 true AR128760A1 (es) 2024-06-12

Family

ID=87936087

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100603A AR128760A1 (es) 2022-03-11 2023-03-10 Vectores de expresión con promotores dobles bidireccionales y sus usos

Country Status (4)

Country Link
US (1) US20230374546A1 (es)
AR (1) AR128760A1 (es)
TW (1) TW202400796A (es)
WO (1) WO2023173078A2 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2710307C2 (ru) * 2013-09-12 2019-12-26 Байомарин Фармасьютикал Инк. Векторы экспрессии фактора viii на основе аденоассоциированного вируса
EP3749756A4 (en) * 2018-02-05 2021-12-08 Audentes Therapeutics, Inc. ELEMENTS OF TRANSCRIPTION REGULATION AND ASSOCIATED USES
TWI851647B (zh) * 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
JP2022530006A (ja) * 2019-04-24 2022-06-27 リジェネックスバイオ インコーポレイテッド 完全ヒト翻訳後修飾抗体による治療剤
WO2021183895A1 (en) * 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors

Also Published As

Publication number Publication date
WO2023173078A2 (en) 2023-09-14
US20230374546A1 (en) 2023-11-23
WO2023173078A3 (en) 2023-10-19
TW202400796A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
Villa et al. Genetic analysis reveals a longevity-associated protein modulating endothelial function and angiogenesis
PE20210915A1 (es) Capsides variantes de virus adenoasociados y su uso para inhibir la angiogenesis
PE20190401A1 (es) Novedosas proteinas de la capside del virus adenoasociado
PE20190129A1 (es) Capsides variantes de virus adenoasociados y metodos de uso de estas
AU2007247929A1 (en) Restoration of visual responses by In Vivo delivery of rhodopsin nucleic acids
CO2022017959A2 (es) Composiciones para la reducción específica de la expresión transgénica en drg.
CN110267980A (zh) 诱导型胱天蛋白酶及使用方法
CO2021016200A2 (es) Composiciones útiles para el tratamiento de la enfermedad de pompe
RU2019142845A (ru) Вирусная экспрессионная конструкция, содержащая кодирующую последовательность фактора роста фибробластов 21 (fgf21)
AR126407A1 (es) Casetes de expresión optimizada para genoterapia
AR128760A1 (es) Vectores de expresión con promotores dobles bidireccionales y sus usos
CO2023001500A2 (es) Composiciones útiles para el tratamiento de la enfermedad de charcot-marie-tooth
CL2023001876A1 (es) Proteínas de la cápside viral con especificidad para las células del tejido cardiaco
CO2022017224A2 (es) Composiciones útiles para el tratamiento de la enfermedad de pompe
PE20240115A1 (es) Construcciones de anticuerpos anti-vegf y metodos relacionados para el tratamiento de los sintomas asociados al schwannoma vestibular
MX2023001419A (es) Vector viral adenoasociado para la expresion de glut1 y usos de este.
PE20230826A1 (es) Peptidos y combinaciones de peptidos para uso en inmunoterapia contra la infeccion por sars-cov-2
CL2023001650A1 (es) Tratamiento de la enfermedad de danon
AR129035A1 (es) Métodos de tratamiento con la terapia génica con placofilina-2
MX2023000995A (es) Vector de genoterapia para eef1a2 y usos del mismo.
AR129122A1 (es) Terapia génica del gen de la proteína 2 del linfoma de células b asociado a atanogén 3 (bag3) mediante un vector aav
BR112023023249A2 (pt) Fator neurotrófico de codificação de vírion aav e usos do mesmo
CL2021002248A1 (es) Composiciones útiles en el tratamiento de la enfermedad de krabbe.
PE20240240A1 (es) Composiciones de administracion de terapia genica y metodos para el tratamiento de la perdida auditiva
US20220193265A1 (en) Methods and compositions for reprogramming müller glia